Back to results
US 2017/0000769 A1Published application
NADPH Production by the 10-Formyl-THF Pathway, and Its Use in the Diagnosis and Treatment of Disease
AssigneeThe Trustees of Princeton University
InventorsJoshua D. Rabinowitz, Jing Fan, Gregory S. Ducker
Life of this patent
Estimating the term…
Abstract
A 10-formyl-THF pathway for producing NADPH is useful in the diagnosis and treatment of cancer and metabolic disease, in the development of new antineoplastic agents and/or regimens, in the development of new methods for measuring metabolic pathway activity, and in the development of new therapeutics for treating metabolic disease.
Claims19
A method of treating cancer in a cancer patient, wherein said method comprises administering to said cancer patient:
- (A) an anti-folate anticancer agent;
- and
- (B) one or more metabolic compounds selected from the group consisting of thymine, a molecule that comprises a thymine moiety, formate, a molecule that comprises a formate moiety, glycine and a purine;
- and
- (C) a pharmaceutically acceptable excipient, carrier or diluent;
- wherein:
- (i) said anti-folate anticancer agent is administered in an amount sufficient to treat said cancer;
- and
- (ii) said metabolic compound(s) is administered in amount(s) sufficient to remediate attenuation of the concentration of said metabolic compound(s) by said anti-folate anticancer agent or to increase the efficiency of said anti-folate anticancer agent.
6 more elements
A pharmaceutical composition comprising:
- (A) an anti-folate anticancer agent;
- and
- (B) one or more metabolic compounds selected from the group consisting of thymine, a molecule that comprises a thymine moiety, formate, a molecule that comprises a formate moiety, glycine and a purine;
- and
- (C) a pharmaceutically acceptable excipient, carrier or diluent;
- wherein said composition contains said anti-folate anticancer agent in an amount sufficient to treat a cancer in a subject and contains said metabolic compound(s) in amount(s) sufficient to remediate attenuation of the concentration of said metabolic compound(s) by said anti-folate anticancer agent or to increase the efficiency of said anti-folate anticancer agent.
3 more elements
Dependencies are inferred from the claim text.